Skip to content

Novo Nordisk A/S Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 4, 2026 results vs estimates

Novo Nordisk A/S · E.NVO.NYSE · United States
Use symbol E.NVO.NYSE in our API & Excel add-in to retrieve this data ↓
39.14
(+0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 0%
Trend -50%
Bubble Risk LOW
Realised Volatility (20D) 20.73%

Novo Nordisk A/S Forecast

Novo Nordisk A/S short-term momentum is neutral (up over 2 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term NEUTRAL signal. The long-term trend is negative (2 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 20.7% a year, a typical one-standard-deviation range is 38.00–40.28 over a week, 36.80–41.48 over a month and 31.03–47.25 over a year. (Signals as of 1 Nov 2026.)

Novo Nordisk A/S Price Chart

MacroFinance.ai

Novo Nordisk A/S Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Novo Nordisk A/S
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Novo Nordisk A/S
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Novo Nordisk A/S
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Novo Nordisk A/S
P/E
1.53x
Cheap vs own history
QoQ −14.2%
YoY −25.2%
now 1.52751.42 low2.67 high
ⓘP/E As of 22 Nov 2026.See Novo Nordisk A/S returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Novo Nordisk A/S
P/S
0.52x
Cheap vs own history
QoQ −17.7%
YoY −22.8%
now 0.51810.5 low0.88 high
ⓘP/S As of 22 Nov 2026.See Novo Nordisk A/S returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Novo Nordisk A/S
P/B
0.79x
Cheap vs own history
QoQ −15.3%
YoY −36.3%
now 0.79370.75 low1.63 high
ⓘP/B As of 22 Nov 2026.See Novo Nordisk A/S returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Novo Nordisk A/S
EV/EBITDA
1.40x
Cheap vs own history
QoQ −16.3%
YoY −15.8%
now 1.39881.37 low2.05 high
ⓘEV/EBITDA As of 22 Nov 2026.See Novo Nordisk A/S returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Novo Nordisk A/S
EV/Sales
0.77x
Cheap vs own history
QoQ −15.7%
YoY −12.9%
now 0.77380.76 low1.1 high
ⓘEV/Sales As of 22 Nov 2026.See Novo Nordisk A/S returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Novo Nordisk A/S
FCF Yield
26.8%
Strong vs own history
QoQ +13.6%
YoY −6.9%
now 26.795713.15 low29.55 high
ⓘFCF Yield As of 22 Nov 2026.See Novo Nordisk A/S returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Novo Nordisk A/S
Earnings Yield
65.5%
Strong vs own history
QoQ +16.6%
YoY +33.6%
now 65.466837.44 low70.34 high
ⓘEarnings Yield As of 22 Nov 2026.See Novo Nordisk A/S returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Novo Nordisk A/S
Dividend Yield
30.1%
Mid-range vs own history
QoQ +19.4%
YoY −33.8%
now 30.090523.36 low45.23 high
ⓘDividend Yield As of 22 Nov 2026.See Novo Nordisk A/S returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Novo Nordisk A/S
Market Cap
$172.9B
Lowest in 5 years
QoQ −16.6%
YoY −18.4%
now 172876.9572160,301 low277,169 high
ⓘMarket Cap As of 22 Nov 2026.See Novo Nordisk A/S returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Novo Nordisk A/S
Net Debt
$85.3B
Mid-range vs own history
QoQ −10.3%
YoY +24.3%
now 8530468,631 low124,756 high
ⓘNet Debt As of 22 Nov 2026.See Novo Nordisk A/S returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Novo Nordisk A/S
Net Debt / EBITDA
0.46x
Mid-range vs own history
QoQ −12.1%
YoY +13.7%
now 0.46220.41 low0.67 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Novo Nordisk A/S returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Novo Nordisk A/S
Current Ratio
0.84x
Mid-range vs own history
QoQ −3.2%
YoY +8.9%
now 0.84490.78 low0.87 high
ⓘCurrent Ratio As of 22 Nov 2026.See Novo Nordisk A/S returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Novo Nordisk A/S
Quick Ratio
0.64x
Mid-range vs own history
QoQ −2.8%
YoY +11.6%
now 0.63970.56 low0.66 high
ⓘQuick Ratio As of 22 Nov 2026.See Novo Nordisk A/S returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Novo Nordisk A/S
Interest Coverage
10.21x
Mid-range vs own history
QoQ +23.8%
YoY +40.5%
now 10.21455.92 low10.21 high
ⓘInterest Coverage As of 22 Nov 2026.See Novo Nordisk A/S returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Novo Nordisk A/S
Debt / Equity
0.62x
Mid-range vs own history
QoQ −2.5%
YoY +3.6%
now 0.61740.6 low0.72 high
ⓘDebt / Equity As of 22 Nov 2026.See Novo Nordisk A/S returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Novo Nordisk A/S
Piotroski F-Score
5
Mid-range vs own history
QoQ 0.0%
YoY +25.0%
now 54 low5 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Novo Nordisk A/S returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Novo Nordisk A/S
Altman Z-Score
2.1
Weak vs own history
QoQ −4.9%
YoY −7.7%
now 2.09732.09 low2.39 high
ⓘAltman Z-Score As of 22 Nov 2026.See Novo Nordisk A/S returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Novo Nordisk A/S, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Novo Nordisk A/S fundamentals: income statement, balance sheet & cash flow

Novo Nordisk A/S reported revenue of $309.06bn and net income of $102.43bn in FY2025, the year ended 31 December 2025 — revenue up 6.4% and net income up 1.4% on the prior year. Free cash flow was $28.99bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$309.06bn
+6.4%
Net income
$102.43bn
+1.4%
Gross margin
80.98%
Free cash flow
$28.99bn
-58.4%
Net debt
$104.49bn
Shares short (30 Oct 2026)
38.29m
4.04 days to cover
Novo Nordisk A/S income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue309.06290.40232.26176.95140.80
Cost of revenue58.7944.5235.7728.4523.66
Gross profit250.28245.88196.50148.51117.14
Research & development52.0448.0632.4424.0517.77
Selling, general & admin.70.5869.4861.4849.6540.73
Operating income127.66128.34102.5774.8158.64
EBITDA156.73147.94114.6376.8065.39
Interest expense4.211.640.540.380.29
Pre-tax income130.54127.19104.6769.0659.08
Income tax28.1126.2020.9913.5411.32
Net income102.43100.9983.6855.5347.76

Download Novo Nordisk A/S fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.NVO.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 41 fiscal years and 165 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Novo Nordisk A/S

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Novo Nordisk A/S Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Novo Nordisk A/S; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Novo Nordisk A/S’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Novo Nordisk A/S behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Novo Nordisk A/S (United States)

Novo Nordisk A/S is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Novo Nordisk A/S

Frequently asked questions

What is Novo Nordisk A/S?
Novo Nordisk A/S is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Novo Nordisk A/S price?
The latest close is 39.14 (1 Nov 2026), +0.02% on the day. The price at the top of the page refreshes during the trading day.
Is Novo Nordisk A/S in an uptrend?
As of 1 Nov 2026, short-term momentum is neutral (2 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is negative (2 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Novo Nordisk A/S?
20-day realised volatility is 20.7% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 6.0% over a month and 2.9% over a week.
What factors affect Novo Nordisk A/S?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Novo Nordisk A/S, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Novo Nordisk A/S?
58 backtested tactical asset allocation strategies trade Novo Nordisk A/S through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Novo Nordisk A/S returns analysed?
The Statistical Distribution of Returns section shows the distribution of Novo Nordisk A/S daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Novo Nordisk A/S historical data?
In the Free historical data section of this page: the last 10 years of Novo Nordisk A/S daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Novo Nordisk A/S historical data (last 10 years)

Browse or instantly download the last 10 years of Novo Nordisk A/S daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.NVO.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2037.82
2026-11-1938.87
2026-11-1839.43
2026-11-1740.7
2026-11-1641.6
2026-11-1341.63
2026-11-1240.65
2026-11-1141.09
2026-11-1040.7
2026-11-0941.38
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.